Medical therapies for hepatocellular carcinoma;Prise en charge médicale du carcinome hépatocellulaire

Cancer/Radiotherapie

Volumn 15, Issue 1, 2011, Pages 28-31

  Merle, P ^a,b,c   Mornex, F ^c,d  

^a HÔTEL DIEU   (France)

^b INSERM   (France)

^c UNIVERSITÉ LYON 1   (France)

^d CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

Antiangiogenics; Chemotherapy; Hepatocellular carcinoma; Hormonotherapy; Interferon; Somatostatine

Indexed keywords

ALPHA INTERFERON; ANTIMITOTIC AGENT; MITOGEN ACTIVATED PROTEIN KINASE; PERETINOIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SEOCALCITOL; SORAFENIB; VASCULOTROPIN RECEPTOR;

ANTIANGIOGENIC THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CHEMOEMBOLIZATION; HUMAN; LIVER CELL CARCINOMA; PRIORITY JOURNAL; SHORT SURVEY;

ANGIOGENESIS INHIBITORS; ANTIMITOTIC AGENTS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; LIVER NEOPLASMS;

EID: 79551508214     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canrad.2010.12.002     Document Type: Short Survey

References (24)

1. Lai C., Wu P., Chan G., Lok A., Lin H. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. Cancer 1988, 62:479-483.
2. Louafi S., Boige V., Ducreux M., Bonyhay L., Mansourbakht T., de Bære T., et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma: results of a phase II study. Cancer 2007, 109:1384-1390.
3. Asnacios A., Fartoux L., Romano O., Tesmoingt C., Louafi S.S., Mansoubakht T., et al. Gemcitabine plus oxaliplatin combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a phase 2 study. Cancer 2008, 112:2733-2739.
4. Di Stefano G., Busi C., Derenzini M., Trere D., Fiume L. Conjugation of 5-fluoro-2(-deoxyuridine with lactosaminated poly-L-lysine to reduce extrahepatic toxicity in the treatment of hepatocarcinomas. Ital J Gastroenterol Hepatol 1998, 30:173-177.
5. Barraud L., Merle P., Soma E., Lefrançois L., Guerret S., Chevallier M., et al. Antitumor activity of doxorubicin-loaded nanoparticles against hepatocellular carcinoma developed in X/myc transgenic mice. J Hepatol 2005, 42:736-743.
6. Yager J.D., Yager R. Oral contraceptive steroids as promoters of hepatocarcinogenesis in female Sprague-Dawley rats. Cancer Res 1980, 40:3680-3685.
7. Francavilla A., Polimeno L., DiLeo A., Barone M., Ove P., Coetzee M., et al. The effect of estrogen and tamoxifen on hepatocyte proliferation in vivo and in vitro. Hepatology 1989, 9:614-620.
8. Farinati F., Salvagnini M., de Maria N., Forniaseri A., Chiaramonte M., Rossaro L., et al. Unresectable hepatocellular carcinoma: a prospective controlled trial with tamoxifen. J Hepatol 1990, 12:297-301.
9. Martinez-Cerezo F.J., Tomas A., Donoso L., Enriquez J., Guarner C., Balanzo J., et al. Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma. J Hepatol 1994, 20:702-706.
10. Castells A., Bruix J., Bru C., Ayuso M.C., Roca M., Boix L., et al. Treatment of hepatocellular carcinoma with tamoxifen: a double blind placebo-controlled trial in 120 patients. Gastroenterology 1995, 109:917-922.
11. Cancer of the Liver Italian Programme (CLIP) Group Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. Lancet 1998, 352:17-20.
12. Nasague N., Ito A., Yukaya H., Ogawa Y. Androgen receptors in hepatocellular carcinoma and surrounding parenchyma. Gastroenterology 1985, 89:643-647.
13. Manesis E.K., Giannoulis G., Zoumboulis P., Vafiadou I., Hadziyannis S.J. Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial. Hepatology 1995, 21:1535-1542.
14. Groupe d'étude et de traitement du carcinome hépatocellulaire A multicenter randomized trial of antiandrogenic treatment in patients with unresectable hepatocellular carcinoma (abstract). Hepatology 1998, 28:345A.
15. Kouroumalis E., Skordilis P., Thermos K., Vasilaki A., Moschandrea J., Manousos O.N. Treatment of hepatocellular carcinoma with octreotide: a randomized controlled study. Gut 1998, 42:442-447.
16. Becker G., Allgaier H.P., Olschewski M., Zähringer A., Blum H.E. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepatology 2007, 45:9-15. HECTOR Study Group.
17. Lai C.L., Lau J.Y.N., Wu P.C., Ngan H., Chung H.T., Mitchell S.J., et al. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized-controlled trial. Hepatology 1993, 17:389-394.
18. Llovet J.M., Sala M., Castells L., Suarez Y., Vilana R., Bianchi L., et al. Randomized-controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000, 31:54-58.
19. Muto Y., Moriwaki H., Ninomiya M., Adachi S., Saito A., Takasaki K.T., et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 1996, 334:1561-1567.
20. Muto Y., Moriwaki H. Antitumor activities of vitamin A and its derivatives. J Natl Cancer Inst 1984, 73:1989-1993.
21. Dalhoff K., Dancey J., Astrup L., Skovsgaard T., Hamberg K.J., Lofts F.J., et al. A phase II study of the vitamin D analogue seocalcitol in patients with inoperable hepatocellular carcinoma. Br J Cancer 2003, 89:252-257.
22. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
23. ®) dans le traitement du carcinome hépatocellulaire: recommandations Prodige Afef. Gastroenterol Clin Biol 2008, 32:3-7.
24. Girard N., Mornex F. Sorafénib et radiothérapie dans le carcinome hépatocellulaire. Cancer Radiother 2011, 15:77-80.